Customer Logins

Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.

Customer Logins

My Logins

All Customer Logins
S&P Global S&P Global Marketplace
Explore S&P Global

  • S&P Global
  • S&P Dow Jones Indices
  • S&P Global Market Intelligence
  • S&P Global Mobility
  • S&P Global Commodity Insights
  • S&P Global Ratings
  • S&P Global Sustainable1
Close
Discover more about S&P Global’s offerings
Investor Relations
  • Investor Relations Overview
  • Investor Presentations
  • Investor Fact Book
  • News Releases
  • Quarterly Earnings
  • SEC Filings & Reports
  • Executive Committee
  • Corporate Governance
  • Merger Information
  • Stock & Dividends
  • Shareholder Services
  • Contact Investor Relations
Languages
  • English
  • 中文
  • 日本語
  • 한국어
  • Português
  • Español
  • ไทย
About
  • About Us
  • Contact Us
  • Email Subscription Center
  • Media Center
  • Glossary
Product Login
S&P Global S&P Global Market Intelligence Market Intelligence
  • Who We Serve
  • Solutions
  • News & Insights
  • Events
  • Product Login
  • Request Follow Up
  •  
    • Academia
    • Commercial Banking
    • Corporations
     
    • Government & Regulatory Agencies
    • Insurance
    • Investment & Global Banking
     
    • Investment Management
    • Private Equity
    • Professional Services
  • WORKFLOW SOLUTIONS
    • Capital Formation
    • Credit & Risk Solutions
    • Data & Distribution
    • Economics & Country Risk
    • Sustainability
    • Financial Technology
     
    • Issuer & IR Solutions
    • Lending Solutions
    • Post-Trade Processing
    • Private Markets
    • Risk, Compliance, & Reporting
    • Supply Chain
    PRODUCTS
    • S&P Capital IQ Pro
    • S&P Global Marketplace
    • China Credit Analytics
    • Climate Credit Analytics
    • Credit Analytics
    • RatingsDirect ®
    • RatingsXpress ®
    • 451 Research
    See More S&P Global Solutions
     
    • Capital Access
    • Corporate Actions
    • KY3P ®
    • EDM
    • PMI™
    • BD Corporate
    • Bond Pricing
    • ChartIQ
  • CONTENT
    • Latest Headlines
    • Special Features
    • Blog
    • Research
    • Videos
    • Infographics
    • Newsletters
    • Client Case Studies
    PODCASTS
    • The Decisive
    • IR in Focus
    • Masters of Risk
    • MediaTalk
    • Next in Tech
    • The Pipeline: M&A and IPO Insights
    • Private Markets 360°
    • Street Talk
    SEE ALL EPISODES
    SECTOR-SPECIFIC INSIGHTS
    • Differentiated Data
    • Banking & Insurance
    • Energy
    • Maritime, Trade, & Supply Chain
    • Metals & Mining
    • Technology, Media, & Telecoms
    • Investment Research
    • Sector Coverage
    • Consulting & Advisory Services
    More ways we can help
    NEWS & RESEARCH TOPICS
    • Credit & Risk
    • Economics & Country Risk
    • Financial Services
    • Generative AI
    • Maritime & Trade
    • M&A
    • Private Markets
    • Sustainability & Climate
    • Technology
    See More
    • All Events
    • In-Person
    • Webinars
    • Webinar Replays
    Featured Events
    Webinar2024 Trends in Data Visualization & Analytics
    • 10/17/2024
    • Live, Online
    • 11:00 AM - 12:00 PM EDT
    In PersonInteract New York 2024
    • 10/15/2024
    • Center415, 415 5th Avenue, New York, NY
    • 10:00 -17:00 CEST
    In PersonDatacenter and Energy Innovation Summit 2024
    • 10/30/2024
    • Convene Hamilton Square, 600 14th St NW, Washington, DC 20005, US
    • 7:30 AM - 5:00 PM ET
  • PLATFORMS
    • S&P Capital IQ Pro
    • S&P Capital IQ
    • S&P Global China Credit Analytics
    • S&P Global Marketplace
    OTHER PRODUCTS
    • Credit Analytics
    • Panjiva
    • Money Market Directories
     
    • Research Online
    • 451 Research
    • RatingsDirect®
    See All Product Logins
Same-Day Analysis

Israeli MoH Adds 71 News Drugs to Country's 2010 Drug Basket But Faces Massive Opposition

Published: 31 December 2009
Israel's committee recommending drugs for inclusion in the country's drug basket has named 71 drugs for inclusion on 2010's list, wile the Ministry of Health has diverted US$9 million from the drugs' budget to dental care, meaning drugs such as Avastin (bevacizumab) have been left out.

IHS Global Insight Perspective

 

Significance

The Israeli committee in charge of recommending annual additions to the country's drug basket has recommended 71 new drugs to be included in the public health insurance scheme from next year. Basic dental care for children will also be free from 2010.

Implications

The additions include drugs for various indications and will cost the government 350 million new shekels (US$95 million) annually. Byetta (exenatide), Champix (varenicline) and Zyban (bupropion) are key drug inclusions for the coming year. The health ministry's plan for paediatric dental care will cost 65 million new shekels, which has been taken out of the previously budgeted 415 million shekels for drugs.

Outlook

The diverting of funds meant for drugs to dental care has meant that drugs like Avastin (bevacizumab) have failed to make it on to the list. Therefore, breast cancer patients may have to wait until 2011 for such drugs to be covered, after a High Court ruling on the matter favoured the free dental care for children programme.

US$95-mil. Worth of Drugs Added to Israel's Positive Reimbursement List

The committee in charge of recommending drugs covered under Israel's public health insurance system has recommended 71 new drugs to be added to the country's "drug basket" next year. The list includes drugs for several indications, such as oncology, haematology, cardiology, neurology, infectious diseases (including HIV/AIDS), nephrology, auto-immune diseases, psychiatry, and opthalomology.

Committee Recommendations For Israeli Drug Basket 2010

Erbitux (cetuximab)

Alimta (pemetrexed)

Iressa (genfitinib)

Afinitor (everolimus)

Sutent (sutinib)

Nexavar (sorafenib)

Torisel (temsirolimus)

Gemzar (gemcitabine)

Herceptin (transtuzumab)

Tykerb (lapatinib)

Glivec (imantinib)

Vectibix (panitumumab)

Mabthera (rituximab)

Velcade (bortezomib)

Mozobil (plerixafor)

Vigam (immunoglobulin)

Thyrogen (thyrotropin)

Intelence (entravirine)

Firazyr (icatibant)

Mimpara (cinacalcet)

Aclasa (zoledronic acid)

Effient (prasugrel)

Xarelto (rovaroxaban)

Pradaxa (dabigatran)

Multaq (dronedarone)

Inspra (eplerenone)

Rasilez (aliskiren)

Eraxis (anidulafungin)

Avonex (interferon beta 1a)

Betaferon (interferon beta 1b)

Copaxone (glatiramer acetate)

Gamunex (IVIG)

Azilect (rasagaline)

Aricept, Asenta, Memorit (donepezil)

Exelon (rivastigimine)

Targin (oxycodone + naloxone)

Provigil (modafinil)

Zemplar (paricalcitol)

Byetta (exenatide)

Victoza (liraglutide)

Diavobet (calcipotriol + betamethosone)

Amevive (alefacept)

Humira (adalimumab)

Enbrel (etanercept)

Remicade (infliximab)

Abilify (aripiprazole)

Zyban (bupropion)

Champix (varenicline)

Arava (leflunomide)

Spiriva (tiotropium)

Combigan (Timolol + Brimonidine)

-

-

-

-

Source: Israeli Health Ministry

Key additions include smoking-cessation drugs—such as GlaxoSmithKline (GSK; U.K.)'s Zyban and Pfizer's Champix—and Eli Lilly (U.S.)'s non-insulin dependent diabetes drug Byetta (exenatide). The most expensive additions are Iressa, Sutent, and Afinitor, for kidney cancer, with coverage for these drugs expected to cost the government 35 million new shekels (US$9 million) annually.

Furthermore several drugs on the list are already part of the drug basket, with 2010's recommendation to see their coverage increased. For example, Teva' s Azliect will now be reimbursed for early-stage Parkinson's disease as well, in line with the drug's proven disease-modifying ability. Similarly, oncology drug Exbitux will also be reimbursed for several oncology indications, including head and neck, and metastatic colon cancer.

Other new technology additions include the addition of an artificial heart valve and new MRI scanner that will improve breast cancer detection. All of the above-mentioned inclusions are worth US$350 million and are set to benefit over 70,000 Israelis revealed Professor Rafael Beyar, the head of the 16-member health basket committee (source: Hareetz). According to Beyar, 66% of the technologies were life saving, while the others extended and improved quality of life.

The Israeli Health Ministry's list of technology included for 201 can be found here.

Free Dental Care for Children

Concurrently, the government has also approved Deputy Minister of Health Ya'acov Litzman's plan to provide free basic dental care to all children from 2010 at a cost of 65 million new shekels. The monies in question have been diverted from a previously budgeted 415-million-shekel drug budget, reports the Jerusalem Post.

Outlook and Implications

The new drug list has some significant additions and is set to increase affordability of all the drugs in the aforementioned drug basket. As indicated before, the addition of smoking cessation drugs and non-insulin dependent diabetes drug are significant and a first in the drug basket, with patients disappointed when these drugs were included in 2009's list (see Israel: 24 December 2008: Israeli Health Ministry to Add 83 New Drugs to 2009 Health Service Basket, Including Erbitux). While the addition of these drugs has pacified some stakeholders, opposition from other sections has in fact increased. Litzman's diversion of drug funds towards paediatric dental care ruffled several feathers, with some members on the health basket committee reportedly also against the move; the matter has even been taken to court. According to the Israeli Medical Association (IMA), the move has seen reduced access to key drugs such as Avastin (bevacizumab) for metastatic breast cancer, which could not make it onto the positive reimbursement list. However, beneficiaries requiring the drug may have to wait for the 2011 drug list, given that a high court ruling has favoured Litzman and the new drug list is set to be finalised shortly.

Although diverting drugs funds in itself is a controversial issue, the inclusion of dental care for children itself is no surprise. The central government's plan to increase its involvement in this matter was announced in mid 2009 (see Israel: 12 June 2009: Israeli Government to Increase Participation in Covering Dental Care for Children).

Related Content
  • Healthcare & Pharma Industry Analysis
{"items" : [ {"name":"share","enabled":true,"desc":"<strong>Share</strong>","mobdesc":"Share","options":[ {"name":"facebook","url":"https://www.facebook.com/sharer.php?u=http%3a%2f%2fwww.spglobal.com%2fmarketintelligence%2fen%2fmi%2fcountry-industry-forecasting.html%3fid%3d106594727","enabled":true},{"name":"twitter","url":"https://twitter.com/intent/tweet?url=http%3a%2f%2fwww.spglobal.com%2fmarketintelligence%2fen%2fmi%2fcountry-industry-forecasting.html%3fid%3d106594727&text=Israeli+MoH+Adds+71+News+Drugs+to+Country%27s+2010+Drug+Basket+But+Faces+Massive+Opposition","enabled":true},{"name":"linkedin","url":"https://www.linkedin.com/sharing/share-offsite/?url=http%3a%2f%2fwww.spglobal.com%2fmarketintelligence%2fen%2fmi%2fcountry-industry-forecasting.html%3fid%3d106594727","enabled":true},{"name":"email","url":"?subject=Israeli MoH Adds 71 News Drugs to Country's 2010 Drug Basket But Faces Massive Opposition&body=http%3a%2f%2fwww.spglobal.com%2fmarketintelligence%2fen%2fmi%2fcountry-industry-forecasting.html%3fid%3d106594727","enabled":true},{"name":"whatsapp","url":"https://api.whatsapp.com/send?text=Israeli+MoH+Adds+71+News+Drugs+to+Country%27s+2010+Drug+Basket+But+Faces+Massive+Opposition http%3a%2f%2fwww.spglobal.com%2fmarketintelligence%2fen%2fmi%2fcountry-industry-forecasting.html%3fid%3d106594727","enabled":true}]}, {"name":"rtt","enabled":true,"mobdesc":"Top"} ]}
Filter Sort
  • About S&P Global Market Intelligence
  • Quality Program
  • Email Subscription Center
  • Media Center
  • Our Values
  • Investor Relations
  • Contact Customer Care & Sales
  • Careers
  • Our History
  • News Releases
  • Support by Division
  • Corporate Responsibility
  • Ventures
  • Quarterly Earnings
  • Report an Ethics Concern
  • Leadership
  • Press
  • SEC Filings & Reports
  • Office Locations
  • IOSCO ESG Rating & Data Product Statements
  • © 2025 S&P Global
  • Terms of Use
  • Cookie Notice
  • Privacy Policy
  • Disclosures
  • Do Not Sell My Personal Information